Trial Profile
An Open-labelled Multicenter Randomized Study on the Efficacy of Everolimus in Reducing Total Native Kidney Volume in Kidney Transplanted Patients With Autosomal Dominant Polycystic Kidney Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Calcineurin inhibitors
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms EVERKYSTE
- 07 Dec 2018 Status changed from recruiting to completed.
- 03 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
- 30 Jun 2014 New trial record